Diabetes Drug Exenatide Shows Promise for Weight Loss in Prediabetic Adults

Stanford University conducted a groundbreaking study to determine whether exenatide, a GLP-1 receptor agonist approved for type 2 diabetes treatment, could prevent diabetes progression in high-risk individuals. The research focused on whether this medication could restore healthy insulin function and promote weight loss in people with prediabetes.

The randomized, placebo-controlled trial enrolled 66 participants with prediabetes and insulin resistance. Half received exenatide injections (5-10 mcg twice daily) while the control group received placebo injections. All participants followed a structured weight loss diet throughout the study period from 2007 to 2013.

Researchers measured critical metabolic markers including first-phase insulin response, insulin sensitivity, blood glucose levels, and body weight changes. They also monitored for potential side effects including hypoglycemia and assessed improvements in cholesterol profiles associated with insulin resistance.

Exenatide works by mimicking GLP-1, a natural hormone that stimulates insulin release when blood sugar rises, slows stomach emptying, and reduces appetite. In diabetic patients, it has demonstrated consistent weight loss and improved blood sugar control. This study aimed to determine if similar benefits occur in prediabetic individuals before permanent beta cell damage occurs.

The trial's completion provides valuable insights into diabetes prevention strategies. By testing exenatide in prediabetic populations, researchers could evaluate the drug's direct effects on insulin function without the confounding factors present in established diabetes. This approach offers potential for early intervention, possibly preventing or delaying type 2 diabetes onset in high-risk individuals through improved metabolic function and sustainable weight management.